The global antiepileptic drugs market ,used to treat epilepsy, is estimated to reach US$ 26.2 billion by 2032. This signifies a projected growth at a Compound Annual Growth Rate (CAGR) of close to 4.3% from its estimated valuation of US$ 17.3 billion in 2022.
Epilepsy is a serious neurological disorder characterized by recurrent seizures that are not caused by temporary factors like high fever or head injury. Left untreated, epilepsy can lead to progressive cognitive decline, neurological damage, and other brain impairments. AEDs play a vital role in managing epilepsy by reducing the frequency and intensity of seizures, thereby improving the quality of life for patients.
Elevate Knowledge: Obtain Your Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-3341
Rising Prevalence of Epilepsy Fuels Market Growth
The significant growth in the antiepileptic drugs market is driven by the increasing prevalence of epilepsy. Second only to headaches in terms of prevalence among neurological disorders, epilepsy represents a major public health concern. It creates a substantial financial burden on healthcare systems and significantly impacts individuals and society as a whole. The chronic nature of epilepsy, with patients often requiring lifelong treatment, further contributes to market expansion.
Growing Awareness and Improved Treatment Options Drive Market Forward
Heightened public awareness about epilepsy and the availability of improved treatment options are additional factors propelling market growth. Increased access to diagnosis and effective AEDs allows for better management of the condition.
This press release highlights the projected expansion of the antiepileptic drugs market. With the rising prevalence of epilepsy and advancements in treatment options, the market is poised for steady growth in the coming years.
Global Antiepileptic Drugs Market Key Takeaways from Market Study
- Second generation of antiepileptic drugs are the leading segment as drug generation, and hold approximately 4% market share in 2021. In comparison to first-generation medications, second generation AEDs have a lower risk of teratogenesis and a more favorable side-effect profile.
- Oral route of administration segment is set to lead in terms of route of administration of antiepileptic drugs with a market share of around 2% in 2021, owing to its ease of administration in pediatric and geriatric patients.
- By distribution channel, retail pharmacies are leading in the global antiepileptic drugs market, and are expected to continue to do so with a projected CAGR of 6% during the forecasted years.
- North America is considered as the leading region with a value share of 6% in 2021, owing to the high prevalence of neurological diseases in the region.
“Rising prevalence of neurological and mood disorders has called for innovations within the antiepileptic drugs market sphere,” says an analyst of Future Market Insights.
Gain Insight Into Our Research Process: https://www.futuremarketinsights.com/request-report-methodology/rep-gb-3341
Global Antiepileptic Drugs Market Competition
Key market leaders are concentrating on receiving regulatory agency approvals, which is anticipated to propel the expansion of the worldwide antiepileptic drugs market. Key players are coming up with new drug profiles to widen their portfolio presence.
For instance:
- Pfizer, Inc. reported in July 2019 that the US Food and Drug Administration has approved the first Lyrica (pregabalin) generics for use as an adjunctive therapy for the management of partial onset seizures in patients aged 17 and older.
- In August 2021, Eisai Co., Ltd. announced that the National Medical Products Administration in China had granted its internally discovered and developed anti-epileptic drug (AED) Fycompa® two additional approvals as “a monotherapy for partial-onset seizures” and “an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older.”
What Does the Report Cover?
Future Market Insights offers a unique perspective and actionable insights on the antiepileptic drugs market in its latest study, presenting a historical demand assessment of 2012 – 2021 and projections for 2022 – 2032. The global antiepileptic drugs market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
The research study is based on the drug generation – (first generation, second generation, and third generation), by route of administration (oral, and intravenous), by distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and drug stores), across seven key regions of the world.
Global Antiepileptic Drugs Market Key Companies Profiled:
- Merck KGaA
- Eisai Co., Ltd.
- AstraZeneca
- Novartis AG
- Abbott
- Teva Pharmaceutical Industries Ltd.
- Pfizer Inc.
- GlaxoSmithKline plc
- Sanofi
- Johnson & Johnson Service, Inc.
- Dr. Reddy’s Laboratories Ltd.
Secure Your Market Analysis Now: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/3341
Key Market Segments Covered in Global Antiepileptic Drugs Market Research:
By Drug Generation:
- First Generation
- Second Generation
- Third Generation
By Route of Administration:
- Oral
- Intravenous
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube